ALK’s partner for Japan reports positive trial results for house dust mite SLIT-tablet

10 March 2014

Denmark-based allergy specialist ALK Abello (ALKB: DC) said that its Japanese partner Torii Pharmaceutical (TSE: 4551) has reported positive results from its Phase II/III trial into ALK’s sublingual allergy immunotherapy tablet (SLIT-tablet) for house dust mite-induced allergic rhinitis (hay fever).

The trial met its primary efficacy endpoint by showing a significantly lower ‘Total Combined Rhinitis Score’ (TCRS) when compared with patients who received placebo. The trial also showed that the treatment was well tolerated and had a favorable safety profile.

ALK’s president and chief executive Jens Bager said: “These results mark another step on our journey towards globalizing ALK’s portfolio of SLIT-tablets. Our partnership with Torii continues to progress rapidly and we are getting closer to a launch of these products in the world’s second largest pharmaceutical market.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK